ArticleFrontiers in genetics2015
Lipid changes due to fenofibrate treatment are not associated with changes in DNA methylation patterns in the GOLDN study.
Article in Frontiers in genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- A systematic review and metaanalysis of observational studies on the effects of epigenetic factors on serum triglycerides.Archives of endocrinology and metabolism · 2022Pooled it
- Obesity I: Overview and molecular and biochemical mechanisms.Biochemical pharmacology · 2022Review
- Fibrate pharmacogenomics: expanding past the genome.Pharmacogenomics · 2020Article
- Aberrant DNA methylation of M1-macrophage genes in coronary artery disease.Scientific reports · 2019Article
- Endocrine-Mediated Mechanisms of Metabolic Disruption and New Approaches to Examine the Public Health Threat.Frontiers in endocrinology · 2019Review
- Quality control for Illumina 450K methylation data in the absence of iDat files using correlation structure in pedigrees and repeated measures.BMC genetics · 2018Article
- Longitudinal data methods for evaluating genome-by-epigenome interactions in families.BMC genetics · 2018Article
- Investigation of parent-of-origin effects induced by fenofibrate treatment on triglycerides levels.BMC genetics · 2018Article
- Homozygosity disequilibrium associated with treatment response and its methylation regulation.BMC proceedings · 2018Article
- Genomic 5-mC contents in peripheral blood leukocytes were independent protective factors for coronary artery disease with a specific profile in different leukocyte subtypes.Clinical epigenetics · 2018Article
- Integrative methylation score to identify epigenetic modifications associated with lipid changes resulting from fenofibrate treatment in families.BMC proceedings · 2018Article
- A Bayesian mixed modeling approach for estimating heritability.BMC proceedings · 2018Article
- Evidence of batch effects masking treatment effect in GAW20 methylation data.BMC proceedings · 2018Article
- DNA methylation as a marker of response in rheumatoid arthritis.Pharmacogenomics · 2017Review
- An epigenome-wide association study of inflammatory response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network.Pharmacogenomics · 2017Article
- Epigenetics of Lipid Phenotypes.Current cardiovascular risk reports · 2016Article
- Blood lipids influence DNA methylation in circulating cells.Genome biology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Fenofibrate lowers triglycerides (TG) and raises high density lipoprotein cholesterol (HDLc) in dyslipidemic individuals. Several studies have shown genetic variability in lipid responses to fenofibrate treatment. It is, however, not known whether epigenetic patterns are also correlated with the changes in lipids due to fenofibrate treatment. The present study was therefore undertaken to examine the changes in DNA methylation among the participants of Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study. A total of 443 individuals were studied for epigenome-wide changes in DNA methylation, assessed using the Illumina Infinium HumanMethylation450 array, before and after a 3-week daily treatment with 160 mg of fenofibrate. The association between the change in DNA methylation and changes in TG, HDLc, and low-density lipoprotein cholesterol (LDLc) were assessed using linear mixed models adjusted for age, sex, baseline lipids, and study center as fixed effects and family as a random effect. Changes in DNA methylation were not significantly associated with changes in TG, HDLc, or LDLc after 3 weeks of fenofibrate for any CpG. CpG changes in genes known to be involved in fenofibrate response, e.g., PPAR-α, APOA1, LPL, APOA5, APOC3, CETP, and APOB, also did not show evidence of association. In conclusion, changes in lipids in response to 3-week treatment with fenofibrate were not associated with changes in DNA methylation. Studies of longer duration may be required to detect treatment-induced changes in methylation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.